Seven-year outcomes following aortic valve replacement with a novel tissue bioprosthesis

被引:9
|
作者
Beaver, Thomas [1 ]
Bavaria, Joseph E. [2 ]
Griffith, Bartley [3 ]
Svensson, Lars G. [4 ]
Pibarot, Philippe [5 ]
Borger, Michael A. [5 ]
Sharaf, Omar M. [1 ]
Heimansohn, David A. [6 ]
Thourani, Vinod H. [7 ]
Blackstone, Eugene H.
Puskas, John D. [8 ]
机构
[1] Univ Florida Hlth, Div Cardiovasc Surg, Gainesville, FL USA
[2] Hosp Univ Penn, Dept Cardiovasc Surg, Philadelphia, PA USA
[3] Univ Maryland, Med Ctr, Dept Surg, Baltimore, MD USA
[4] Cleveland Clin, Dept Thorac & Cardiovasc Surg, Cleveland, OH USA
[5] Laval Univ, Quebec Heart & Lung Inst, Dept Cardiol, Quebec City, PQ, Canada
[6] St Vincent Heart Ctr Indiana, Indianapolis, IN USA
[7] Piedmont Heart Inst, Marcus Valve Ctr, Dept Cardiovasc Surg, Atlanta, GA USA
[8] Mt Sinai Morningside, Dept Cardiovasc Surg, New York, NY USA
来源
关键词
aortic valve replacement; aortic valve disease; bioprosthetic valve; RESILIA tissue; PRESERVATION TECHNOLOGY; DEFINITIONS; GUIDELINES; DABIGATRAN; WARFARIN; FAILURE;
D O I
10.1016/j.jtcvs.2023.09.047
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: As bioprosthetic aortic valve replacement (AVR) extends to younger cohorts, tissue durability is of paramount importance. We report 7-year outcomes from an AVR bioprosthesis utilizing novel tissue. Methods: This was an international investigational device exemption trial for novel AVR with annual follow-up and a subset re-consented at 5 years for extended 10-year follow-up. Safety end points and echocardiographic measurements were adjudicated by an independent clinical events committee and by a dedicated core laboratory, respectively. Results: Between January 2013 and March 2016, 689 patients underwent AVR with the study valve. Mean age was 66.9 +/- 11.6 years, Society of Thoracic Surgeons risk score was 2.0% % +/- 1.8%, % , and 74.3% % of patients were New York Heart Association functional class II and III. Five-year follow-up was completed by 512 patients, and 225 re-consented for extended follow-up. Follow-up duration was 5.3 +/- 2.2 years (3665.6 patient-years), and 194 and 195 patients completed 6-and 7-year follow-ups, respectively. One-, 5-, and 7-year freedom from all-cause mortality was 97.7%, % , 89.4%, % , and 85.4%, % , respectively. Freedom from structural valve deterioration at 7 years was 99.3%. % . At 7 years, effective orifice fi ce area and mean gradients were 1.82 +/- 0.57 cm(2) (n = 153), and 9.4 +/- 4.5 mm Hg (n = 157), respectively. At 7 years, predominantly none (96.8% % [152 out of 157]) or trivial/trace (2.5% % [4 out of 157]) paravalvular regurgitation and none (84.7% % [133 out of 157]) or trivial/trace (11.5% % [18 out of 157]) transvalvular regurgitation were observed. Conclusions: We report the longest surgical AVR follow-up with novel tissue in an investigational device exemption trial utilizing an independent clinical events committee and an echocardiography core laboratory. This tissue demonstrates excellent outcomes through 7 years and is the benchmark for future surgical and transcatheter prostheses.
引用
收藏
页码:781 / 791
页数:11
相关论文
共 50 条
  • [31] Antithrombotic therapy and bleeding events after aortic valve replacement with a novel bioprosthesis
    Klautz, Robert J. M.
    Vriesendorp, Michiel D.
    Dagenais, Francois
    Labrousse, Louis
    Bapat, Vinayak
    Moront, Michael G.
    Misfeld, Martin
    Gearhart, Elizabeth
    Kappetein, A. Pieter
    Sabik, Joseph F., III
    JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2021, 161 (01): : 66 - +
  • [32] A novel approach to tricuspid valve replacement: The upside down stentless aortic bioprosthesis
    Cardarelli, MG
    Gammie, JS
    Brown, JM
    Poston, RS
    Pierson, RN
    Griffith, BP
    ANNALS OF THORACIC SURGERY, 2005, 80 (02): : 507 - 510
  • [33] Ten-year outcome after aortic valve replacement with the freestyle stentless bioprosthesis
    Bach, DS
    Kon, ND
    Dumesnil, JG
    Sintek, CF
    Doty, DB
    ANNALS OF THORACIC SURGERY, 2005, 80 (02): : 480 - 487
  • [34] Eight-year results after aortic valve replacement with the freestyle stentless bioprosthesis
    Bach, DS
    Kon, ND
    Dumesnil, JG
    Sintek, CF
    Doty, DB
    JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2004, 127 (06): : 1657 - 1663
  • [35] Aortic valve replacement with the Cryolife-OBrien stentless aortic bioprosthesis: five-year experience
    Martinovic, I
    Farah, I
    Everlien, M
    Knez, I
    Greve, H
    Vogt, P
    JOURNAL OF CARDIOVASCULAR SURGERY, 2004, 45 (06): : 557 - 563
  • [36] STENTLESS PORCINE BIOPROSTHESIS FOR AORTIC-VALVE REPLACEMENT
    GOLDMAN, BS
    DAVID, TE
    DELRIZZO, DF
    SEVER, J
    BOS, J
    JOURNAL OF CARDIOVASCULAR SURGERY, 1994, 35 (06): : 105 - 110
  • [37] PERFORMANCE OF THE HANCOCK PORCINE BIOPROSTHESIS FOLLOWING AORTIC-VALVE REPLACEMENT - CONSIDERATIONS BASED ON A 15-YEAR EXPERIENCE
    MILANO, AD
    BORTOLOTTI, U
    MAZZUCCO, A
    GUERRA, F
    STELLIN, G
    TALENTI, E
    THIENE, G
    GALLUCCI, V
    ANNALS OF THORACIC SURGERY, 1988, 46 (02): : 216 - 222
  • [38] Frailty and clinical outcomes following aortic valve replacement
    Ram, Eilon
    Peled, Yael
    Miller, Tali B.
    Dray, Efrat M.
    Karni, Ehud
    Raanani, Ehud
    Sternik, Leonid
    JOURNAL OF CARDIAC SURGERY, 2022, 37 (10) : 3036 - 3043
  • [39] Conduction disturbances following surgical aortic valve replacement with a rapid-deployment bioprosthesis
    Coti, Iuliana
    Schukro, Christoph
    Drevinja, Fitim
    Haberl, Thomas
    Kaider, Alexandra
    Kocher, Alfred
    Laufer, Guenther
    Andreas, Martin
    JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2021, 162 (03): : 803 - 811
  • [40] AORTIC-VALVE REPLACEMENT WITH A STENTLESS PORCINE BIOPROSTHESIS
    GOLDMAN, BS
    DAVID, TE
    DELRIZZO, D
    YACOUB, M
    ALDRETE, V
    JOYNER, C
    MURPHY, P
    RAKOWSKI, H
    MCCALLUM, L
    CIRCULATION, 1994, 90 (04) : 310 - 310